| 篇纂]項下的[編纂]數目 : [編纂]股H股(視乎[編纂] | | | --- | --- | | 行使與否而定) | | | 香港[編纂]數目 [编纂]股H股(可予重新分配) | :: | | 國際[編纂]數目 [編纂]股H股(可予車新分配及 | | | 視乎[編纂]行使與否而定) | | | 最高[編纂] : 每股[編纂][編纂]港元,另加1.0% | | | 經紀佣金、0.0027%證監會交易 | | | 徵費、0.00565%聯交所交易費及 | | | 0.00015%會財局交易徵費(須於申請 | | | 時以港元繳足,多繳款項可予退還) | | | 間值 每股H股人民幣1.00元 | : | | 『4巨笛1 · 「拒笛1 | | 智通财经APP获悉，据港交所12月31日披露，景泽生物医药(合肥)股份有限公司-B(简称：景泽生物)向港 交所主板递交上市申请，中金公司、国元国际为联席保荐人。该公司曾于2025年6月27日向港交所递表。 公司简介 据招股书，该公司是一家历史可追溯至2014年，专注于辅助生殖药物和眼科药物两大赛道的生物制药公 司。该公司拥有：(1)两项核心产品，其中(a)JZB30为注 ...

香港聯合交易所有限公司與證券及期貨事務監察委員會對本申請版本的內容概不負責，對其準確性或完整 性亦不作任何陳述，並明確表示對因本申請版本的全部或任何部分內容而引致或因依賴本申請版本的全部 或任何部分內容而引致的任何損失不負任何責任。 Jingze Biopharmaceutical (Hefei) Co., Ltd 景澤生物醫藥（合肥）股份有限公司 （「本公司」） （於中華人民共和國註冊成立的股份有限公司） 的申請版本 警告 本申請版本乃根據香港聯合交易所有限公司（「聯交所」）與證券及期貨事務監察委員會（「證監會」）的要求 而刊發，僅用作提供資訊予香港公眾人士。 本申請版本為草擬本，其所載資料並不完整，亦可能會作出重大變動。 閣下閱覽本文件，即代表 閣下 知悉、接納並向本公司、其聯席保薦人、整體協調人、顧問或包銷團成員表示同意： 本公司招股章程根據香港法例第32章公司（清盤及雜項條文）條例呈交香港公司註冊處處長註冊前，本公 司不會向香港公眾人士提出要約或邀請。倘於適當時候向香港公眾人士提出要約或邀請，有意投資者務請 僅依據呈交香港公司註冊處處長註冊的本公司招股章程作出投資決定；招股章程的文本將於發售期內向公 ...

The Stock Exchange of Hong Kong Limited and the Securities and Futures Commission take no responsibility for the contents of this Application Proof, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this Application Proof. Application Proof of Jingze Biopharmaceutical (Hefei) Co., Ltd 景澤生物醫藥 (合 肥 )股份有限公司 (the "Company") (A joint stock company incorporated i ...

Core Viewpoint - Jingze Biopharma is preparing for an IPO, focusing on high-growth areas of assisted reproduction and ophthalmic drugs, with a pre-IPO valuation of 3.09 billion RMB after completing multiple funding rounds [1][2]. Company Overview - Jingze Biopharma specializes in assisted reproduction and ophthalmic drugs, having developed a comprehensive R&D system and commercial-scale production capabilities [2]. - The company has eight candidate drugs, with its first core product expected to generate revenue by 2026 [2][7]. Product Pipeline - The core product JZB30, a recombinant human follicle-stimulating hormone (rhFSH) lyophilized injection, is crucial in assisted reproduction and has received NDA approval [4][7]. - Another key product, JZB05, is an anti-VEGF intravitreal injection aimed at treating wet age-related macular degeneration (wAMD) and diabetic macular edema (DME), with expectations for commercialization by 2026 [5][6]. Market Potential - The assisted reproduction market is expanding due to relaxed fertility policies, with an estimated 59.2 million couples affected by infertility in China by 2024, projected to grow to 68.4 million by 2030 [8]. - The ophthalmic drug market is also growing, with a projected increase from 29.5 billion RMB in 2024 to 53.7 billion RMB by 2030, driven by rising rates of blindness-related eye diseases [12][13]. Financial Outlook - Jingze Biopharma is currently not profitable, with projected losses of 246 million RMB and 243 million RMB for 2023 and 2024, respectively [7]. - The company anticipates revenue generation starting in 2026 with the commercialization of JZB30, while R&D costs will continue to be a significant expense [7].

Core Viewpoint - Jingze Biopharmaceutical (Hefei) Co., Ltd. has submitted its prospectus for an IPO on the Hong Kong Stock Exchange, facing challenges due to significant losses and a reliance on a single approved drug while having multiple candidates in development [1][8]. Group 1: Company Overview - Jingze Biopharmaceutical was established in 2014, focusing on assisted reproduction and ophthalmic drugs, and is one of the leading companies in China for clinical-stage macromolecule drugs in these fields [2][3]. - The company has eight drug candidates, with only one product, JZB30, approved for commercialization in the assisted reproduction sector [3][4]. Group 2: Product Pipeline - JZB30, a recombinant human follicle-stimulating hormone lyophilized powder injection, was approved by the National Medical Products Administration in April 2025, targeting the global ovulation market [3]. - JZB33, a biosimilar to the imported drug Ganirelix, has completed bioequivalence studies and an NDA has been submitted [4]. - In the ophthalmic sector, JZB05, an anti-VEGF intravitreal injection, is in Phase III clinical trials, with an NDA submission expected in the second half of 2026 [4]. Group 3: Financial Performance - Jingze Biopharmaceutical reported losses of CNY 246 million and CNY 243 million for 2023 and 2024, respectively, with R&D expenses of CNY 122 million and CNY 133 million [5]. - As of the end of 2024, the company had cash and cash equivalents of CNY 68.59 million, with net current liabilities increasing to CNY 1.325 billion [5]. Group 4: Funding and Future Plans - The company has raised a total of CNY 927 million through various funding rounds from 2018 to 2023, with a post-investment valuation of CNY 3.09 billion in the C+ round [5]. - The IPO proceeds are intended to advance clinical trials and production development for multiple pipelines [5]. Group 5: Operational Challenges - Jingze Biopharmaceutical relies heavily on third-party contract research organizations (CROs) for preclinical and some clinical trials, which poses risks related to timely delivery and compliance [6]. - The company plans to establish a sales network in collaboration with well-known domestic pharmaceutical companies to distribute JZB30 and has partnered with Nanjing Jianyou for U.S. market registration of JZB33 [6]. Group 6: Market Strategy - The company aims to build a business team to assist partners in market development, although this requires significant time and funding [7]. - The success of the company is highly dependent on the successful development and commercialization of its drug candidates, which are primarily in preclinical or clinical stages [7].